All In Biotech

Drug Trial Radar · NCT06004245

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Vividion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.

Conditions

  • Advanced Solid Tumors
  • Colorectal Cancer

Interventions

  • VVD-133214Drug

    VVD-133214 will be administered orally and once daily (QD) in 3-week cycles.

  • PembrolizumabDrug

    Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.

  • BevacizumabDrug

    Bevacizumab will be administered by intravenous (IV) infusion at a fixed dose of 7.5 mg/kg on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)Time frame: From first dose of study drug(s) until 30 days after the final dose of VVD-133214 or 90 days after last dose of bevacizumab or pembrolizumab
  2. Incidence of Dose-Limiting ToxicitiesTime frame: Cycle 1 (1 cycle is 3 weeks)

Locations

57 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona · Not yet recruiting

  • City of Hope Cancer Center

    Duarte, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • START Los Angeles

    Los Angeles, California · Recruiting

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Not yet recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Not yet recruiting

  • Norton Cancer Institute - MDC

    Louisville, Kentucky · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Duke University

    Durham, North Carolina · Completed

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma · Completed

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • West Virginia University Cancer Institute

    Morgantown, West Virginia · Not yet recruiting

  • St Vincents Sydney

    Darlinghurst, New South Wales, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Cliniques universitaires de Saint Luc

    Brussels, Belgium · Not yet recruiting

  • UZ Leuven Gasthuisberg

    Ghent, Belgium · Recruiting

  • UZ Gent

    Ghent, Belgium · Not yet recruiting

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, Canada · Completed

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The Sixth Hospital, affiliated with Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Rigshospitalet

    København Ø, Denmark · Recruiting

  • CLCC Leon Berard Lyon

    Lyon, France · Completed

  • Institut regional du Cancer de Montpellier

    Montpellier, France · Not yet recruiting

  • Hôpital saint Antoine

    Paris, France · Not yet recruiting

  • Hopital europeen Georges Pompidou

    Paris, France · Not yet recruiting

  • Oncopole Claudius Regaud

    Toulouse, France · Not yet recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Sarawak Public Hospital

    Kuching, Sarawak, Malaysia · Recruiting

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea · Recruiting

  • National Cancer Center

    Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.